Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: Mol Cancer Ther. 2020 May 5;19(6):1255–1265. doi: 10.1158/1535-7163.MCT-19-0931

Figure 2:

Figure 2:

Response to FGFR inhibitor AZD4547 in seven NSCLC cell lines.

AZD4547 proliferation dose response curves for: A) NCI-H1581, (B) NCI-H226, (C) NCI-H358, (D) NCI-H520, (E) NCI-3122, (F) A549, (G) NCI-H2228. (H) Cell line IC50 sensitivity determined by proliferation assay, (I) clonogenic survival following varying doses of AZD4547 of three high-FGFR expressing cell lines, (J) Western blot downstream signaling analysis of AZD4547 treated NSCLC cell lines. NCI-H1581, NCI-H226 and NCI-H520 cells were treated for 10 minutes, 1 hour, 6 hours and 24 hours with 0.1 μM AZD4547. Columns, mean; bars, SEM (n=3).